In the era of immune checkpoint inhibitors, cytoreductive nephrectomy retains an important role in mRCC in carefully selected patients, according to investigators.
Possible reasons for the survival disparity include differences in obesity and smoking incidence among Black men younger than 50 years.
Patients with PD-L1 expression at initial transurethral resection for bladder cancer were more likely to harbor invasive disease, according to investigators.
Validation of the cytokine markers within the entire NIVOREN study is ongoing.
Neoadjuvant enfortumab vedotin demonstrated promising initial results in a small number of cisplatin-ineligible patients with muscle-invasive bladder cancer, according to investigators.
Early-salvage radiation therapy was associated with reduced risks for biochemical recurrence and metastasis, compared with expectant management.
Screening for sarcopenia may assist in identifying patients at high risk for increased perioperative morbidity, according to investigators.
Patients receiving immunotherapy had a more durable immune response to vaccination, compared with patients receiving chemotherapy or targeted therapy.
Adjuvant mitotane does not improve outcomes in patients with adrenocortical carcinoma at low or intermediate risk of relapse after surgery.
New findings could inform personalized therapeutic strategies for patients with renal cell carcinoma, according to investigators.
Intravesical bacillus Calmette-Guérin remains effective in patients with prior radiation treatment for prostate cancer, according to a study.
Sequential intravesical gemcitabine and docetaxel could provide an effective treatment option during an ongoing BCG shortage.
In a phase 2 trial, 44% of men who received abiraterone with or without cabazitaxel prior to radical prostatectomy for high-risk prostate cancer achieved a pathologic complete response or minimal residual disease.
The immunotherapy N-803 appears to boost innate immune memory and prolong the duration of response to therapy.
The 5-year metastasis-free survival was similar with trimodal therapy and radical cystectomy.
The median progression-free survival was similar between the treatment arms.
The study’s primary endpoint was met, and neoadjuvant chemotherapy was considered well tolerated.
Compared with German and US patients, UK patients were less likely to be diagnosed with prostate cancer via routine screening.
Bone loss was observed in both treatment arms, but abiraterone plus prednisone did not increase bone loss.
By blinded independent review, there was a 39% reduction in the risk of progression or death with olaparib.